Combining radiation plus immunotherapy to improve systemic immune response

被引:48
作者
Cushman, Taylor R. [1 ]
Gomez, Daniel [1 ]
Kumar, Rachit [1 ,2 ]
Likacheva, Anna [1 ,2 ]
Chang, Joe Y. [1 ]
Cadena, Alex P. [1 ]
Paris, Sebastien [3 ]
Welsh, James W. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Banner MD Anderson Canc Ctr, Dept Radiat Oncol, Phoenix, AZ USA
[3] Nanobiotix, Dept Biol Discovery, Paris, France
关键词
Immunotherapy; radiation therapy (RT); radiotherapy; abscopal; lung cancer; CELL LUNG-CANCER; STEREOTACTIC ABLATIVE RADIOTHERAPY; 1ST-LINE THERAPY; TUMOR-STROMA; PHASE-II; T-CELLS; TRIAL; RESISTANCE; MELANOMA; PD-1;
D O I
10.21037/jtd.2018.01.130
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Over the past decade, the fields of oncology have made great strides in therapies. The development of new therapeutics and increased understanding of the role of the immune system in the development and treatment of cancer has led to increased collaboration between oncologic fields. Recent technologic advancements in radiation therapy (RT), including stereotactic beam radiation therapy (SBRT), have improved local control and offer an alternative to surgery for the control of oligometastatic disease. Immunotherapy has proven a promising therapeutic in the treatment of metastatic disease but treatment resistance remains a significant obstacle in the majority of patients. Together, radiation and immunotherapy offer potential to eliminate metastatic disease, reduce time to recurrence and improve overall survival. Major obstacles to these positive outcomes include high tumor burden, intratumoral heterogeneity, and the negative effects of tumor stroma, to name a few. Multimodality treatments are under heavy investigation. Promising data from clinical trials is emerging to highlight the value of RT in combination with immunotherapy. However, the mechanisms behind their synergistic effects remain to be fully elucidated. This review aims to highlight the existing literature and offers hypotheses to explain mechanisms behind the synergy of RT and immunotherapy.
引用
收藏
页码:S468 / S479
页数:12
相关论文
共 49 条
[31]   An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease [J].
Salama, Joseph K. ;
Chmura, Steven J. ;
Mehta, Neil ;
Yenice, Kamil M. ;
Stadler, Walter M. ;
Vokes, Everett E. ;
Haraf, Daniel J. ;
Hellman, Samuel ;
Weichselbaum, Ralph R. .
CLINICAL CANCER RESEARCH, 2008, 14 (16) :5255-5259
[32]   Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy Going Beyond Local Control [J].
Schoenhals, Jonathan E. ;
Seyedin, Steven N. ;
Tang, Chad ;
Cortez, Maria A. ;
Niknam, Sharareh ;
Tsouko, Efrosini ;
Chang, Joe Y. ;
Hahn, Stephen M. ;
Welsh, James W. .
CANCER JOURNAL, 2016, 22 (02) :130-137
[33]   PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients [J].
Schulze, Arik Bernard ;
Schmidt, Lars Henning .
JOURNAL OF THORACIC DISEASE, 2017, 9 (04) :E384-E386
[34]   Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis [J].
Senthi, Sashendra ;
Lagerwaard, Frank J. ;
Haasbeek, Cornelis J. A. ;
Slotman, Ben J. ;
Senan, Suresh .
LANCET ONCOLOGY, 2012, 13 (08) :802-809
[35]   Propensity Scoree-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy [J].
Sheu, Tommy ;
Heymach, John V. ;
Swisher, Stephen G. ;
Rao, Ganesh ;
Weinberg, Jeffrey S. ;
Mehran, Reza ;
McAleer, Mary Frances ;
Liao, Zhongxing ;
Aloia, Thomas A. ;
Gomez, Daniel R. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (04) :850-857
[36]   Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancers in the Elderly [J].
Shirvani, Shervin M. ;
Jiang, Jing ;
Chang, Joe Y. ;
Welsh, James ;
Likhacheva, Anna ;
Buchholz, Thomas A. ;
Swisher, Stephen G. ;
Smith, Benjamin D. .
JAMA SURGERY, 2014, 149 (12) :1244-1253
[37]   7-Year Follow-Up After Stereotactic Ablative Radiotherapy for Patients With Stage I Non-Small Cell Lung Cancer: Results of a Phase 2 Clinical Trial [J].
Sun, Bing ;
Brooks, Eric D. ;
Komaki, Ritsuko U. ;
Liao, Zhongxing ;
Jeter, Melenda D. ;
McAleer, Mary F. ;
Allen, Pamela K. ;
Balter, Peter A. ;
Welsh, James D. ;
O'Reilly, Michael S. ;
Gomez, Daniel ;
Hahn, Stephen M. ;
Roth, Jack A. ;
Mehran, Reza J. ;
Heymach, John V. ;
Chang, Joe Y. .
CANCER, 2017, 123 (16) :3031-3039
[38]   Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm [J].
Tekatli, Hilal ;
van't Hof, Saar ;
Nossent, Esther J. ;
Dahele, Max ;
Verbakel, Wilko F. A. R. ;
Slotman, Ben J. ;
Senan, Suresh .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (06) :974-982
[39]   Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer [J].
Timmerman, Robert ;
McGarry, Ronald ;
Yiannoutsos, Constantin ;
Papiez, Lech ;
Tudor, Kathy ;
DeLuca, Jill ;
Ewing, Marvene ;
Abdulrahman, Ramzi ;
DesRosiers, Colleen ;
Williams, Mark ;
Fletcher, James .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4833-4839
[40]   Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer [J].
Timmerman, Robert ;
Paulus, Rebecca ;
Galvin, James ;
Michalski, Jeffrey ;
Straube, William ;
Bradley, Jeffrey ;
Fakiris, Achilles ;
Bezjak, Andrea ;
Videtic, Gregory ;
Johnstone, David ;
Fowler, Jack ;
Gore, Elizabeth ;
Choy, Hak .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (11) :1070-1076